Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract

International Journal of Cancer

Volumn 118, Issue 11, 2006, Pages 2665-2671

  He, Xiao Yang ^a   Tang, Lili ^b   Wang, Shou Lin ^a   Cai, Qing Song ^b   Wang, Jia Sheng ^b   Hong, Jun Yan ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Aflatoxin B1; Cytochrome P450 2A13; Cytotoxicity; Metabolic activation

Indexed keywords

AFLATOXIN B1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A; CYTOCHROME P450 2A13; CYTOCHROME P450 3A4; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; EPOXIDATION; EXPOSURE; INHALATION; LIVER CARCINOGENESIS; LUNG CANCER; LUNG CARCINOGENESIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM;

AFLATOXIN B1; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHO CELLS; CRICETINAE; EPOXY COMPOUNDS; HUMANS; INHALATION EXPOSURE; LUNG NEOPLASMS;

EID: 33646346615     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21665     Document Type: Article

References (57)

1. IARC working group on the evaluation of carcinogenic risks to humans. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum 2002;82:1-556.
2. National toxicology program. Report on carcinogens, 11th ed. NIEHS, National Institute of Health, 2005. 8p.
3. Lilleberg SL, Cabonce MA, Raju NR, Wagner LM, Kier LD. Alterations in the structural gene and the expression of p53 in rat liver tumors induced by aflatoxin B1. Mol Carcinog 1992;6:159-72.
4. Lilleberg SL, Cabonce MA, Raju NR, Wagner LM, Kier LD. Alterations in the p53 tumor suppressor gene in rat liver tumors induced by aflatoxin B1. Prog Clin Biol Res 1992;376:203-22.
5. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994;264:1317-9.
6. McMahon G, Davis EF, Huber LJ, Kim Y, Wogan GN. Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors. Proc Natl Acad Sci USA 1990;87:1104-8.
7. Eaton DL, Groopman JD. The toxicology of aflatoxins: human health, veterinary, and agricultural significance. San Diego, CA: Academic Press, 1994.
8. Massey TE. The 1995 Pharmacological Society of Canada Merck Frosst Award. Cellular and molecular targets in pulmonary chemical carcinogenesis: studies with aflatoxin B1. Can J Physiol Pharmacol 1996;74:621-8.
9. Sorenson WG, Simpson JP, Peach MJ, Thedell TD, Olenchock SA. Aflatoxin in respirable corn dust particles. J Toxicol Environ Health 1981;7:669-72.
10. Hayes RB, Van Nieuwenhuize JP, Raatgever JW, ten Kate FJW. Aflatoxin exposures in the industrial setting: an epidemiological study of mortality. Food Chem Toxicol 1984;22:39-43.
11. Dvorackova I. Aflatoxin inhalation and alveolar cell carcinoma. Br Med J 1976;1:691.
12. 1 activation in human lung. Toxicol Appl Pharmacol 1997;144:88-95.
13. Burg WA, Shotwell OL, Saltzman BE. Measurements of airborne aflatoxins during handling of contaminated corn. Am Ind Hyg Assoc J 1981;42:1-11.
14. Harrison JC, Garner RC. Immunological and HPLC detection of aflatoxin adducts in human tissues after an acute poisoning incident in S.E. Asia. Carcinogenesis 1991;12:741-3.
15. Dickens F, Jones HEH, Waynforth HB. Oral, subcutaneous and intratracheal administration of carcinogenic lactones and related substances: the intratracheal administration of cigarette tar in the rat. Br J Cancer 1966;20:134-44.
16. Wieder R, Wogan GN, Shimkin MB. Pulmonary tumors in strain A mice given injections of aflatoxin B1. J. Natl Cancer Inst 1968;40:1195-7.
17. Stoner GD. Lung tumors in strain A mice as a bioassay for carcinogenicity of environmental chemicals. Exp Lung Res 1991;17:405-23.
18. Bujons J, Hsieh DP, Kado NY, Messeguer A. Aflatoxin M1 8,9-epoxide: preparation and mutagenic activity. Chem Res Toxicol 1995;8:328-32.
19. Ramsdell HS, Parkinson A, Eddy AC, Eaton DL. Bioactivation of aflatoxin B1 by human liver microsomes: role of cytochrome P450 IIIA enzymes. Toxicol Appl Pharmacol 1991;108:436-47.
20. 1 and comparison to CYP1A2 and CYP2A3. Carcinogenesis 1991;12:355-9.
21. Gallagher EP, Kunze KL, Stapleton PL, Eaton DL. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol Appl Pharmacol 1996;141:595-606.
22. Battista JR, Marnett LJ. Prostaglandin H synthase-dependent epoxidation of aflatoxin B1. Carcinogenesis 1985;6:1227-9.
23. Liu L, Daniels JM, Stewart RK, Massey TE. In vitro prostaglandin H synthase- and monooxygenase-mediated binding of aflatoxin B1 to DNA in guinea-pig tissue microsomes. Carcinogenesis 1990;11:1915-9.
24. Liu L, Massey TE. Bioactivation of aflatoxin B1 by lipoxygenases, prostaglandin H synthase and cytochrome P450 monooxygenase in guinea-pig tissues. Carcinogenesis 1992;13:533-9.
25. Donnelly PJ, Devereux TR, Foley JF, Maronpot RR, Anderson MW, Massey TE. Activation of K-ras in aflatoxin B1-induced lung tumors from AC3F1 (A/J x C3H/HeJ) mice. Carcinogenesis 1996;17:1735-40.
26. Donnelly PJ, Stewart RK, Ali SL, Conlan AA, Reid KR, Petsikas D, Massey TE. Biotransformation of aflatoxin B1 in human lung. Carcinogenesis 1996;17:2487-94.
27. Autrup H, Essigmann FM, Croy RG, Trump BF, Wogan GN, Harris CC. Metabolism of aflatoxin B1 and identification of the major aflatoxin B1-DNA adducts formed in cultured human bronchus and colon. Cancer Res 1979;39:694-8.
28. Stoner GD, Daniel FB, Schenck KM, Schut HAJ, Sandwisch DW, Gohara AF. DNA binding and adduct formation of aflatoxin B1 in cultured human and animal tracheobronchial and bladder tissues. Carcinogenesis 1982;3:1345-8.
29. Essigmann JM, Green CL, Croy RG, Fowler KW, Buchi GH, Wogan GN. Interactions of aflatoxin B1 and alkylating agents with DNA: structural and functional studies. Cold Spring Harb Symp Quant Biol 1983;47(Pt 1):327-37.
30. Pelkonen O, Raunio H. Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environ Health Perspect 1997;105(Suppl 4):767-74.
31. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990;29:1322-9.
32. Ding S, Lake BG, Friedberg T, Wolf CR. Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J 1995;306:161-6.
33. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996;24:1212-7.
34. Crespi CL, Penman BW, Leakey JAE, Arlotto MP, Stark A, Parkinson A, Turner T, Steimel DT, Rudo K, Davies RL, Langenbach R. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 1990;11:1293-300.
35. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone. Cancer Res 2000;60:5074-9.
36. Bao Z, He XY, Ding X, Prabhu S, Hong JY. Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos 2005;33:258-61.
37. Scholl PF, Musser SM, Groopman JD. Synthesis and characterization of aflatoxin B1 mercapturic acids and their identification in rat urine. Chem Res Toxicol 1997;10:1144-51.
38. Egner PA, Yu X, Johnson JK, Nathasingh CK, Groopman JD, Kensler TW, Roebuck BD. Identification of aflatoxin M1-N7-guanine in liver and urine of tree shrews and rats following administration of aflatoxin B1. Chem Res Toxicol 2003;16:1174-80.
39. He XY, Shen J, Hu WY, Ding X, Lu AY, Hong JY. Identification of Va1117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. Arch Biochem Biophys 2004;427:143-53.
40. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsime. II. Solubilization, purification, and properties. J Biol Chem 1964;239:2379-85.
41. Wang SL, He XY, Hong JY. Human cytochrome p450 2S1: lack of activity in the metabolic activation of several cigarette smoke carcinogens and in the metabolism of nicotine. Drug Metab Dispos 2005;33:336-40.
42. O'Gorman S, Fox DT, Wahl GM. Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science (Washington, DC) 1991;251:1351-5.
43. Lafontaine M, Delsaut P, Morelle Y, Taicert A. Aflatoxins: Sampling and analysis in animal feed production plant. Cahiers Notes Documentaires 1994;156:297-305.
44. Autrup JL, Schmidt J, Seremet T, Autrup H. Exposure to aflatoxin B in animal feed production plant workers. Environ Health Perspect 1993;99:195-7.
45. Ghosh SK, Desai MR, Pandya GL, Venkaiah K. Airborne aflatoxin in the grain processing industries in India. Am Ind Hyg Assoc J 1997;59:583-6.
46. Nuntharatanapong N, Suramana T, Chaemthanorn S, Zapuang R, Ritta E, Semathong S, Chuamorn S, Niyomwan V, Dusitsin N, Lohinavy O, Sinhaseni P. Increase in tumor necrosis factor-α and a change in the lactate dehydrogenase isoenzyme pattern in plasma of workers exposed to aflatoxin-contaminated feeds. Arh Hig Rada Toksikol 2001;52:291-8.
47. Mace K, Aguilar F, Wang JS, Vautravers P, Gomez-Lechon M, Gonzalez FJ, Groopman J, Harris CC, Pfeifer AM. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 1997;18:1291-7.
48. Mace K, Bowman ED, Vautravers P, Shields PG, Harris CC, Pfeifer AM. Characterization of xenobiotic-metabolizing enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer 1998;34:914-20.
49. Raunio H, Hakkola J, Hukkanen J, Pelkonen O, Edwards R, Boobis A, Anttila S. Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl 1998;20:465-9.
50. Raunio H, Hakkola J, Hukkanen J, Lassila A, Paivarinta K, Pelkonen O, Anttila S, Piipari R, Boobis A, Edwards RJ. Expression of xenobiotic- metabolizing CYPs in human pulmonary tissue. Exp Toxicol Pathol 1999;51:412-7.
51. Shimada T, Yun CH, Yamazaki H, Gautier JC, Beaune PH, Guengerich FP. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol 1992;41:856-64.
52. Hukkanen J, Lassila A, Paivarinta K, Valanne S, Sarpo S, Hakkola J, Pelkonen O, Raunio H. Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 2000;22:360-6.
53. He XY, Shen J, Ding X, Lu AY, Hong JY. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Drug Metab Dispos 2004;32:1516-21.
54. Ueng YF, Shimada T, Yamazaki H, Guengerich FP. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem Res Toxicol 1995;8:218-25.
55. Raney KD, Meyer DJ, Ketterer B, Harris TM, Guengerich FP. Glutathione conjugation of aflatoxin B1 exo- and endo-epoxides by rat and human glutathione S-transferases. Chem Res Toxicol 1992;5:470-8.
56. Johnson WW, Ueng YF, Widersten M, Mannervik B, Hayes JD, Sherratt PJ, Ketterer B, Guengerich FP. Conjugation of highly reactive aflatoxin B1 exo-8,9-epoxide catalyzed by rat and human glutathione transferases: estimation of kinetic parameters. Biochemistry 1997;36:3056-60.
57. Johnson WW, Yamazaki H, Shimada T, Ueng YF, Guengerich FP. Aflatoxin B1 8,9-epoxide hydrolysis in the presence of rat and human epoxide hydrolase. Chem Res Toxicol 1997;10:672-6.